NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Forecast & News

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) issued its quarterly earnings results on Wednesday, February, 12th. The company reported $0.62 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.61 by $0.01. The company earned $4.47 billion during the quarter, compared to the consensus estimate of $4.35 billion. Teva Pharmaceutical Industries had a negative net margin of 5.75% and a positive return on equity of 16.49%. Teva Pharmaceutical Industries's revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.53 EPS. View Teva Pharmaceutical Industries' Earnings History.

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Wednesday, February, 12th. The company provided earnings per share (EPS) guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.47. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $17.14 billion.

23 equities research analysts have issued 1-year target prices for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $11.75 in the next year. This suggests that the stock has a possible downside of 3.5%. View Analyst Price Targets for Teva Pharmaceutical Industries.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.

Headlines about TEVA stock have trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a news impact score of 0.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Teva Pharmaceutical Industries.

Some companies that are related to Teva Pharmaceutical Industries include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL) and Beigene (BGNE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Intel (INTC), Bank of America (BAC), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (1.82%), Migdal Insurance & Financial Holdings Ltd. (1.16%), Menora Mivtachim Holdings LTD. (0.77%), Commerzbank Aktiengesellschaft FI (0.72%), Harel Insurance Investments & Financial Services Ltd. (0.49%) and Sumitomo Mitsui Trust Holdings Inc. (0.37%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone, Sol J Barer and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Renaissance Technologies LLC, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Commerzbank Aktiengesellschaft FI, Acadian Asset Management LLC, Caisse DE Depot ET Placement DU Quebec, Janus Henderson Group PLC and Cubist Systematic Strategies LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

TEVA stock was bought by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Migdal Insurance & Financial Holdings Ltd., Harel Insurance Investments & Financial Services Ltd., Banco Bilbao Vizcaya Argentaria S.A., Beck Mack & Oliver LLC, Van ECK Associates Corp, UBS Asset Management Americas Inc. and Virtu Financial LLC. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone, Sol J Barer and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $12.18.

Teva Pharmaceutical Industries has a market capitalization of $13.30 billion and generates $16.89 billion in revenue each year. The company earns $-2,150,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 42,535 workers across the globe.View Additional Information About Teva Pharmaceutical Industries.

The official website for Teva Pharmaceutical Industries is http://www.tevapharm.com/.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]